Cytokeratin 14/16 (S5) polyclonal antibody

In Bowen’s disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inheritied skin disorder characterized by skin blistering due to basal keratinocyte fragility.Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN) .

Keratin, type I cytoskeletal 14; Cytokeratin-14; Short name=CK-14; Keratin-14; Short name=K14; KRT14; CK-14; CK 14; CK14; Cytokeratin-14; Cytokeratin 14; Cytokeratin14; Keratin, type I cytoskeletal 16; Cytokeratin-16; Short name=CK-16; Keratin-16; Short name=K16; KRT16; KRT16A; CK-16; CK 16; CK16; Cytokeratin-16; Cytokeratin 16; Cytokeratin16

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Western blot (WB) analysis of KRT14 pAb at 1:500 dilution Lane1:Myla2059 whole cell lysate (40ug) Lane2:EC9706 whole cell lysate (40ug) Lane3:SP2/0 whole cell lysate (40ug) Lane4:C6 whole cell lysate (40ug)